Dishman Carbogen Amcis Limited — PPTs, 20-05-2026: Investor Presentation

Dishman Carbogen Amcis (DCAL) delivered solid Q4FY26 and FY26 results! Net Revenue jumped 18.9% to ₹851.4 Cr in Q4 and 8.1% to ₹2,931.9 Cr for the full year. The CDMO segment was a growth engine, up 21.3% in Q4 and 6.5% for FY26, boosted by commercial sales and late Phase III development. Marketable Molecules also shined, growing 9.3% in Q4 and 17.2% for FY26, driven by higher Vitamin D analogue supplies and better costs.

Full-year EBITDA margin expanded to 19.3%, reflecting improved efficiency. DCAL's strategy focuses on high-value, complex molecules and leveraging its 10 late-stage Phase III molecules. The company is actively targeting small/mid-sized global biotech clients and sees oncology as a key growth area. Recent highlights include renewed GMP certifications for Netherlands and Shanghai facilities, and a reduced net debt of CHF 146.80 mn. Capex for FY26 was CHF 22.4 mn.